Next Article in Journal
Molecular Mechanisms Underlying Yatein-Induced Cell-Cycle Arrest and Microtubule Destabilization in Human Lung Adenocarcinoma Cells
Previous Article in Journal
Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies
Open AccessArticle

Encapsulated Carbenoxolone Reduces Lung Metastases

1
The Institute for Drug Research, The School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, 9112102 Jerusalem, Israel
2
Department of Cell Biology and Cancer Science, The Ruth and Bruce Rappaport Faculty of Medicine, Technion—Israel Institute of Technology, Efron 1, 3535422 Haifa, Israel
3
The Institute of Pulmonary Medicine at Hadassah-Hebrew University Medical Center, 9112102 Jerusalem, Israel
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(9), 1383; https://doi.org/10.3390/cancers11091383
Received: 11 July 2019 / Revised: 23 August 2019 / Accepted: 9 September 2019 / Published: 17 September 2019
Carbenoxolone is an anti-inflammatory compound and a derivate of a natural substance from the licorice plant. We previously showed that carbenoxolone reduces the metastatic burden in the lungs of mice through its antagonistic effect on high mobility group box 1 (HMGB1). To further enhance carbenoxolone’s activity and localization in the lungs, thereby reducing the potential adverse side effects resulting from systemic exposure, we developed a poly(lactic-co-glycolic acid) (PLGA) slow-release system for pulmonary delivery which maintains drug activity in-vitro, as demonstrated in the anoikis assay. Both systemic and intranasal administrations of carbenoxolone effectively minimize metastatic formation in a lung colonization model in mice. Our results show a decrease in the metastatic burden in the lung tissue. Notably, the therapeutic effect of a single intranasal administration of 25 mg/kg carbenoxolone, in the form of drug-loaded particles, had a similar effect in reducing metastatic lesions in the lungs to that of a 10-fold dose of the free drug via intraperitoneal injections, three times per week over the course of four weeks. These data offer new means to potentiate the anti-cancer activity of carbenoxolone and simultaneously reduce the requirement for high dosage administration; the upshot substantially improves therapeutic effect and avoidance of side effects. View Full-Text
Keywords: cancer; carbenoxolone; lungs; metastases; particles; drug delivery; double emulsion; intranasal administration cancer; carbenoxolone; lungs; metastases; particles; drug delivery; double emulsion; intranasal administration
Show Figures

Figure 1

MDPI and ACS Style

Karsch-Bluman, A.; Avraham, S.; Assayag, M.; Schwob, O.; Benny, O. Encapsulated Carbenoxolone Reduces Lung Metastases. Cancers 2019, 11, 1383.

AMA Style

Karsch-Bluman A, Avraham S, Assayag M, Schwob O, Benny O. Encapsulated Carbenoxolone Reduces Lung Metastases. Cancers. 2019; 11(9):1383.

Chicago/Turabian Style

Karsch-Bluman, Adi; Avraham, Shimrit; Assayag, Miri; Schwob, Ouri; Benny, Ofra. 2019. "Encapsulated Carbenoxolone Reduces Lung Metastases" Cancers 11, no. 9: 1383.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop